Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

8 Results

Guidelines and Advice

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

Guidelines and Advice

Chemotherapy (i.e., Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) for Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma

Status: Archived
ID: GL 11-11

Jul 2012

Guidelines and Advice

Safe Administration of Chemotherapy: Safety During Chemotherapy Ordering, Transcribing, Dispensing, and Patient Identification

Status: In-Review
ID: 12-12-1

Jul 2012

Guidelines and Advice

Safe Administration of Chemotherapy: Methods and Development

Status: In-Review
ID: 12-12M

Jul 2012

Guidelines and Advice

Prevention and Outpatient Management of Febrile Neutropenia in Adult Cancer Patients: Clinical Practice Guideline

Status: Current
ID: GL-C50-27

Nov 2021

Guidelines and Advice

Position Statements for Nursing Practice in Cancer Care

Status: Current
Version: 2

May 2021

Guidelines and Advice

Pandemic Planning Clinical Guideline for Patients with Cancer

Status: Current
Version: 2

Dec 2021

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update

Status: Current
ID: 7-A-2018-3

Feb 2021